☆ 4.5 Article

Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort

DIGESTIVE AND LIVER DISEASE (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR

Roberta D'Ambrosio et al.

Summary: This study evaluated the incidence of liver-related and non-liver-related events, as well as mortality, in cirrhotic patients treated with DAAs, finding that patient history significantly influences long-term outcomes. Hepatocellular carcinoma was the most common liver-related complication after viral cure in HCV-related cirrhotic patients, who also faced a significant proportion of non-liver-related events due to improved long-term outcomes.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease

Georg Semmler et al.

Summary: The study developed risk stratification algorithms for de novo HCC development after SVR in patients with ACLD. Parameters such as post-treatment AFP, alcohol consumption, age, LSM, and albumin accurately predicted de novo HCC development and stratified patients into low- and high-risk groups. These algorithms identified approximately two-thirds of patients with cACLD as having a low risk of <1%/year for HCC development, showing effectiveness in risk assessment and surveillance.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis

Myung-Won You et al.

Summary: Evidence consistently demonstrated the predictive value of LSM for HCC occurrence in CHC patients treated with DAA. The significant influencing factor for risk of HCC occurrence indicated by LSM was study design.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Hepatocellular carcinoma

Josep M. Llovet et al.

Summary: Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge with rising incidence projected to exceed 1 million cases by 2025. Infection by hepatitis B and C viruses remains a major risk factor for HCC, while non-alcoholic steatohepatitis is emerging as a more common risk factor in Western countries. Advances in systemic therapies for HCC, including immunotherapies and targeted therapies, are expected to revolutionize the management of this disease.

NATURE REVIEWS DISEASE PRIMERS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity

Lisette A. P. Krassenburg et al.

Summary: In chronic HCV infection, DAA-induced SVR is associated with a reduced risk of clinical disease progression in patients with Child-Pugh A cirrhosis. However, in patients with Child-Pugh B/C cirrhosis, SVR does not seem to have an impact on clinical disease progression.

JOURNAL OF HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents

Fasiha Kanwal et al.

HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals

Monica Pons et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status

Etienne Audureau et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis

Sonia Alonso Lopez et al.

HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study

Fabrice Carrat et al.

LANCET (2019)

Add to Collection

Article Gastroenterology & Hepatology

Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience

Luca Rinaldi et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

Add to Collection

Article Gastroenterology & Hepatology

Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores

George N. Ioannou et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Medicine, Research & Experimental

Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Luca Rinaldi et al.

JOURNAL OF TRANSLATIONAL MEDICINE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection

Elisabetta Degasperi et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

George N. Ioannou et al.

GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals

Federico Ravaioli et al.

DIGESTIVE AND LIVER DISEASE (2018)

Add to Collection

Article Gastroenterology & Hepatology

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs

Pierre Nahon et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Vincenza Calvaruso et al.

GASTROENTEROLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Antonietta Romano et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Peter R. Galle et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C

George N. Ioannou et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

Adriaan J. van der Meer et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Review Gastroenterology & Hepatology

Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression

Reem Waziry et al.

JOURNAL OF HEPATOLOGY (2017)

Add to Collection

Article Immunology

Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C

Magnus Hedenstierna et al.

CLINICAL INFECTIOUS DISEASES (2016)

Add to Collection

Article Gastroenterology & Hepatology

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Editorial Material Gastroenterology & Hepatology

PITER: An ongoing nationwide study on the real-life impact of direct acting antiviral based treatment for chronic hepatitis C in Italy

Loreta A. Kondili et al.

DIGESTIVE AND LIVER DISEASE (2015)

Add to Collection

Article Gastroenterology & Hepatology

Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C

L Castéra et al.

GASTROENTEROLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.